Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 47Squamous Cell Carcinoma of Head and Neck 19Carcinoma, Non-Small-Cell Lung 15Neoplasms 12Head and Neck Neoplasms 9Neoplasm Metastasis 8Lung Neoplasms 8Carcinoma, Squamous Cell 7Pancreatic Neoplasms 6Colonic Neoplasms 6Solid Tumors 5Rectal Neoplasms 4Mouth Neoplasms 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Gastrointestinal Neoplasms 3Colorectal Cancer Metastatic 3Carcinoma 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Recurrence 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Melanoma 2Locally Recurrent Rectal Cancer 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Pancreatic Ductal 2Advanced Solid Tumor 2

Interventions

defactinib 1Oxaliplatin 1Cetuximab 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Colorectal Cancer × Cetuximab × Clear all
NCT06369259 2026-05-20

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

M.D. Anderson Cancer Center

Phase 2 Recruiting
33 enrolled
Gastrointestinal

Advanced Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡